Generation Bio | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 1.594 M

Revenue: As of FY2025 Q3, the actual value is USD 1.594 M, beating the estimate of USD 550 K.

EPS: As of FY2025 Q3, the actual value is USD -0.82, beating the estimate of USD -9.34.

Financial Metrics by Segment

Segment Revenue

• The report does not provide specific segment revenue details.

Operational Metrics

• The report does not provide specific operational metrics such as net income, gross margin, operating profit, operating margin, or operating costs.

Cash Flow

• The report does not provide specific cash flow details.

Unique Metrics

• The report does not provide any unique company-specific financial indicators.

Outlook / Guidance

• The report does not include any forward-looking statements or guidance.

Cash Position

• Cash, cash equivalents, and marketable securities were $89.6 million as of September 30, 2025, compared to $185.2 million as of December 31, 2024.

Research and Development (R&D) Expenses

• R&D expenses were $21.7 million for the quarter ended September 30, 2025, compared to $15.1 million for the quarter ended September 30, 2024.

General and Administrative (G&A) Expenses

• G&A expenses were $12.2 million for the quarter ended September 30, 2025, compared to $9.2 million for the quarter ended September 30, 2024.

Net Loss

• Net loss was $5.5 million, or $0.82 basic and diluted net loss per share, for the quarter ended September 30, 2025, compared to a net loss of $15.3 million, or $2.29 basic and diluted net loss per share, for the quarter ended September 30, 2024.

Lease Settlement

• In August 2025, Generation Bio entered into a settlement agreement to resolve litigation with the landlord of a facility in Waltham, MA, paying a lump sum of $31.0 million and recording a gain on lease termination of $25.5 million.

Collaboration Revenue

• Collaboration revenue was $1.6 million for the quarter ended September 30, 2025, compared to $7.6 million for the quarter ended September 30, 2024.

Loss from Operations

• Loss from operations was $6.7 million for the quarter ended September 30, 2025, compared to $17.9 million for the quarter ended September 30, 2024.

Outlook / Guidance

• Generation Bio is evaluating strategic alternatives to maximize shareholder value, with no assurance of pursuing or completing any transaction. The company expects its cash resources to fund operating expenses for the foreseeable future.